Table 3.

Safety Summary From the Main Baseline (Day −29) to End of Study at Day 120 (All Randomized Patients)

Treatment Group	Alirocumab 150 mg Q4W+Placebo (n=24)	Alirocumab 150 mg Q4W+Ezetimibe (n=24)	Alirocumab 150 mg Q4W+Fenofibrate (n=24)
Subjects with any TEAEs, n (%)	12 (50.0)	14 (58.3)	12 (50.0)
Most frequent TEAEs (recorded in ≥2 subjects in any group), n (%)
Headache	3 (12.5)	5 (20.8)	2 (8.3)
Nasopharyngitis	3 (12.5)	4 (16.7)	4 (16.7)
Influenza	2 (8.3)	0 (0)	1 (4.2)
Gastroenteritis viral	0 (0)	0 (0)	2 (8.3)
Influenza‐like illness	1 (4.2)	3 (12.5)	1 (4.2)
Abdominal pain	2 (8.3)	1 (4.2)	1 (4.2)

Q4W indicates every 4 weeks; TEAE, treatment‐emergent adverse event.